{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:40:05Z","timestamp":1776487205383,"version":"3.51.2"},"reference-count":22,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,4,15]]},"DOI":"10.2169\/internalmedicine.5736-25","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T22:08:20Z","timestamp":1758146900000},"page":"1138-1142","source":"Crossref","is-referenced-by-count":0,"title":["Severe Immune Checkpoint Inhibitor-associated Gastritis Treated with Steroids and Infliximab"],"prefix":"10.2169","volume":"65","author":[{"given":"Koki","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Morisawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Fumihara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Sako","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Momose","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Furumatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Osaka Saiseikai Nakatsu Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Butterfield LH, Najjar YG. Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol 24: 399-416, 2024.","DOI":"10.1038\/s41577-023-00973-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Barbari C, Fontaine T, Parajuli P, et al. Immunotherapies and combination strategies for immuno-oncology. Int J Mol Sci 21: 5009, 2020.","DOI":"10.3390\/ijms21145009"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Suijkerbuijk KPM, van Eijs MJM, van Wijk F, Eggermont AMM. Clinical and translational attributes of immune-related adverse events. Nat Cancer 5: 557-571, 2024.","DOI":"10.1038\/s43018-024-00730-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ruf T, Kramer R, Forschner A, et al. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors. Eur J Cancer 203: 114028, 2024.","DOI":"10.1016\/j.ejca.2024.114028"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hayashi Y, Hosoe N, Takabayashi K, et al. Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced gastroenterocolitis. Dig Dis Sci 66: 2129-2134, 2021.","DOI":"10.1007\/s10620-020-06441-w"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sugiyama Y, Tanabe H, Matsuya T, et al. Severe immune checkpoint inhibitor-associated gastritis: a case series and literature review. Endosc Int Open 10: E982-E989, 2022.","DOI":"10.1055\/a-1839-4303"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Farha N, Faisal MS, Allende DS, et al. Characteristics of immune checkpoint inhibitor-associated gastritis: report from a major tertiary care center. Oncologist 28: 706-713, 2023.","DOI":"10.1093\/oncolo\/oyad031"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cijauskaite E, Kazenaite E, Strainiene S, Sadauskaite G, Kurlinkus B. Nivolumab-induced tumour-like gastritis: a case report. World Clin Cases 11: 4350-4359, 2023.","DOI":"10.12998\/wjcc.v11.i18.4350"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ebisutani N, Tozawa K, Matsuda I, et al. A case of severe acute gastritis as an immune-related adverse event after nivolumab treatment: endoscopic and pathological findings in nivolumab-related gastritis. Dig Dis Sci 66: 2461-2465, 2021.","DOI":"10.1007\/s10620-020-06529-3"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Woodford R, Briscoe K, Tustin R, Jain A. Immunotherapy-related gastritis: two case reports and literature review. Clin Med Insights Oncol 15: 11795549211028570, 2021.","DOI":"10.1177\/11795549211028570"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Saito K, Ozono D, Nagumo H, Yoshimura M, Masuzawa Y. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report. Clin J Gastroenterol 15: 368-373, 2022.","DOI":"10.1007\/s12328-021-01582-5"},{"key":"12","unstructured":"12. Lin J, Lin ZQ, Zheng SC, Chen Y. Immune checkpoint inhibitor-associated gastritis: patterns and management. World J Gastroenterol 29: 5181-5192, 2023."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology 76: 531-539, 2020.","DOI":"10.1111\/his.14029"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology 76: 233-243, 2020.","DOI":"10.1111\/his.13963"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takahashi Y, Nagaya T, Iwaya Y, et al. CD8<sup>+<\/sup> lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors. Dig Dis Sci 68: 451-459, 2023.","DOI":"10.1007\/s10620-022-07598-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Irshaid L, Robert ME, Zhang X. Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, <i>Helicobacter pylori<\/i> gastritis and celiac disease. Arch Pathol Lab Med 145: 191-200, 2021.","DOI":"10.5858\/arpa.2019-0700-OA"},{"key":"17","unstructured":"17. Brahmer JR, Lacchetti C, Schneider BJ, et al.; the National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. JCO 36: 1714-1768, 2018."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Puzanov I, Diab A, Abdallah K, et al.; the Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer: Toxicity Management Working Group. J Immunother Cancer 5: 95, 2017.","DOI":"10.1186\/s40425-017-0300-z"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Haanen JBAG, Carbonnel F, Robert C, et al.; the ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: 119-142, 2017.","DOI":"10.1093\/annonc\/mdx225"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Bresteau C, Bonnet P, Robert C, et al. Serious immune-related upper gastrointestinal toxicity of immune checkpoint inhibitors: a multicenter case series. J Gastroenterol Hepatol 38: 2104-2110, 2023.","DOI":"10.1111\/jgh.16349"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tomsitz D, Ruf T, Zierold S, French LE, Heinzerling L. Steroid-refractory immune-related adverse events induced by checkpoint inhibitors. Cancers 15: 2538, 2023.","DOI":"10.3390\/cancers15092538"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Brongiel S, Rychalsky KL, Luon D, Johnson AR, Price C, Abdelghany C. Management of steroid-refractory gastrointestinal immune-related adverse events. Ann Pharmacother 57: 148-155, 2023.","DOI":"10.1177\/10600280221094330"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/8\/65_5736-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:50:51Z","timestamp":1776484251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/8\/65_5736-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5736-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"5736-25"}}